In a race to develop a vaccine for COVID-19, the biopharmaceutical industry has worked at “unheard-of speed,” National Pharmaceutical Council CSO Robert Dubois writes in a recent Health Affairs blog post.
With that, he writes, it’s time to get a leg up on pricing discussions.
“Fortunately, medicine has a long tradition of identifying and grappling with hard questions,” Dubois writes. “And there is no doubt that it is now the time to come together, roll up our sleeves, and have these difficult – but critical – conversations.”
To read the full write up, click here.